Literature DB >> 21927674

Hepatitis a in developed country, the result should interpret carefully.

Seyed-Moayed Alavian1.   

Abstract

Entities:  

Year:  2011        PMID: 21927674      PMCID: PMC3166686          DOI: 10.5009/gnl.2011.5.3.395

Source DB:  PubMed          Journal:  Gut Liver        ISSN: 1976-2283            Impact factor:   4.519


× No keyword cloud information.
Dear Editor, I read with interest the published article by Chung et al.1 recently in your journal. Hepatitis A virus (HAV) infection continues to be a major health problem worldwide. Prevalence of HAV infection differs greatly in various parts of the world according to the geographic area, sanitary conditions and socioeconomic levels.2 As the authors presented the prevalence rate for anti-HAV Ab increased significantly, studies in various communities have shown that HAV prevalence rises with age.3 It will emphasize the need anti HAV vaccine during childhood in Korea especially when the symptomatic HAV infections have remarkably reported in Korea been increased during recent years.4 But there are some points that can help the readers for better understanding the issue. The living place of study group was urban and it may under-estimate the real prevalence of anti-HAV Ab in general population in Korea. In changing the developing countries to developed countries, the improvement in health status in not uniform and there are heterogeneity in distribution in every country.5 These limitation prevent for final conclusion regarding all of country in Korea, however the result is very important for health policy makers for any decision in future. The decreasing tendency of seropositivity of hepatitis A virus (HAV) in young healthy Korean adults was observed in our study1 and this epidemiological shift was shown in changing the developing countries to developed countries.2-4 The point that we suggest was the catch-up vaccination for young adults especially 20s who have only 6.2% of HAV seropositivity because they are vulnerable to severe symptomatic infection. Also, the prevalence of HAV antibody was lower in high income group and the H. pylori-negative group among young adults (<50 aged), the groups are also considerable to candidates to screening for protective antibodies against HAV and vaccination because the mortality rate of hepatitis A becomes higher at older age.5 However, the improvement in health status is not uniform in the same country and the seroprevalence can be heterogeneity in distribution. Although the living place of subjects was not exactly evaluated in this study, most our subjects were collected in urban and high income group was relatively a large portion as we have already mentioned as a limitation of our study. It may underestimate the real prevalence of seroprevalence of HAV in general young population in Korea. According to a recent study based on the latest nationwide survey in Korea,6 the persons in their 20s in 2009 were found to be the most vulnerable to the infection of HAV with the lowest antibody positive rates (10.4% to 13.3%) regarding all of country evaluated including rural area. Thus, catch-up vaccination for young adults with a low antibody positive rated is to be considered in Korea. However, health policy in every country should be individualized.
  10 in total

1.  Seroepidemiology of hepatitis A virus infection among schoolchildren in Taiwan.

Authors:  Chin-Feng Tsai; Ding-Bang Lin; Shiuan-Chih Chen; Yih-Hsin Chang; Chien-Yi Chen; Jye-Bin Lin
Journal:  J Med Virol       Date:  2011-02       Impact factor: 2.327

2.  A nationwide seroprevalence of total antibody to hepatitis A virus from 2005 to 2009: age and area-adjusted prevalence rates.

Authors:  Donghun Lee; Moran Ki; Anna Lee; Kyoung Ryul Lee; Hee Bong Park; Chang Sub Kim; Bo Young Yoon; Jong Hyun Kim; Young Sok Lee; Sook Hyang Jeong
Journal:  Korean J Hepatol       Date:  2011-03

3.  Hepatitis A.

Authors:  Seyed Moayed Alavian
Journal:  Aust Fam Physician       Date:  2011-04

4.  Seroepidemiology of hepatitis A virus in children of different age groups in Tehran, Iran: implications for health policy.

Authors:  Masoomeh Sofian; Arezoo Aghakhani; Ali-Asghar Farazi; Mohammad Banifazl; Gelavizh Etemadi; Saeed Azad-Armaki; Abolhassan Ziazarifi; Zohreh Abhari; Ali Eslamifar; Akbar Khadem-Sadegh; Nabiallah Izadi; Amitis Ramezani
Journal:  Travel Med Infect Dis       Date:  2010-03-11       Impact factor: 6.211

5.  The changing epidemiologic pattern of hepatitis A infection in urban Greece.

Authors:  J Kremastinou; V Kalapothaki; D Trichopoulos
Journal:  Am J Epidemiol       Date:  1984-11       Impact factor: 4.897

6.  Hepatitis A virus infection: Is it an important hazard to public health?: hazards of HAV for public health.

Authors:  Mehdi Saberifiroozi
Journal:  Hepat Mon       Date:  2011-04       Impact factor: 0.660

7.  Seroprevalence of hepatitis a and associated socioeconomic factors in young healthy korean adults.

Authors:  Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Seon Hee Lim; Min Jung Park; Young Sun Kim; Sun Young Yang; Jong In Yang; Sang-Heon Cho
Journal:  Gut Liver       Date:  2011-03-16       Impact factor: 4.519

8.  Trends in hepatitis A virus infection with reference to the process of urbanization in the greater Madrid area (Spain).

Authors:  C Amela; I Pachón; R Bueno; C de Miguel; F Martinez-Navarro
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

9.  Hepatitis a in Korea: epidemiological shift and call for vaccine strategy.

Authors:  Donghun Lee; Young-Ae Cho; Youngsoo Park; Jin-Hyuk Hwang; Jin Wook Kim; Na Young Kim; Dong Ho Lee; Wonwoo Lee; Sook-Hyang Jeong
Journal:  Intervirology       Date:  2008-04-22       Impact factor: 1.763

10.  Factors influencing the severity of acute viral hepatitis A.

Authors:  Joo Il Kim; Yun Soo Kim; Young Kul Jung; Oh Sang Kwon; Yeon Suk Kim; Yang Suh Ku; Duck Joo Choi; Ju Hyun Kim
Journal:  Korean J Hepatol       Date:  2010-09
  10 in total
  2 in total

1.  Hepatitis A Is a Health Hazard for Iranian Pilgrims Who Go to Holly Karbala: A Preliminary Report.

Authors:  Roya Ghasemian; Farhang Babamahmoodi; Fatemeh Ahangarkani
Journal:  Hepat Mon       Date:  2016-05-25       Impact factor: 0.660

2.  Prevention of hepatitis a virus infection, need to vaccinate or not?

Authors:  Pegah Karimi Elizee; Seyed-Moayed Alavian
Journal:  Int J Prev Med       Date:  2013-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.